Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy : Future Perspectives
Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to in...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (224 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993560439504498 |
|---|---|
| ctrlnum |
(CKB)5680000000080797 (oapen)https://directory.doabooks.org/handle/20.500.12854/92141 (EXLCZ)995680000000080797 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Vermehren, Charlotte edt Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Basel MDPI Books 2022 1 electronic resource (224 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system. English Medicine bicssc Pharmaceutical industries bicssc acute kidney injury early biomarker plasma neutrophil gelatinase-associated lipocalin soluble urokinase plasminogen activator receptor medication optimization older patients emergency department multimorbidity polypharmacy potentially inappropriate medication use older adults prevalence determinants chronic outpatient 2019 Beers criteria Ethiopia pharmacogenomics persons with diabetes drug–drug interactions drug–gene interactions cytochrome P450 SLCO1B1 drug interaction checkers adverse drug reactions pharmacogenetics personalized medicine phenprocoumon DOACs bleeding thromboembolism HLA drug hypersensitivity abacavir allopurinol flucloxacillin antiepileptic drugs cost-effectiveness shared medication record medication reconciliation drug information service hospital pharmacy service electronic prescribing electronic medical record clinical pharmacist CYP2D6 CYP2D7P CYP2D8P copy number variation CNV genotyping 5’nuclease assay HRM high resolution melting drug metabolization extracellular vesicles exosomes microvesicles pharmacogene expression medication review deprescriptions quality of life aged aged, 80 and over nursing homes deprescribing medication-based risk score health outcomes cytochromes CYP1A2 adverse drug reaction antipsychotics olanzapine clozapine loxapine children youth digital decision-support health services research general practice process evaluation antidepressants utility population-based appropriateness medication adherence digital health 3-0365-5162-X 3-0365-5161-1 Westergaard, Niels edt Vermehren, Charlotte oth Westergaard, Niels oth |
| language |
English |
| format |
eBook |
| author2 |
Westergaard, Niels Vermehren, Charlotte Westergaard, Niels |
| author_facet |
Westergaard, Niels Vermehren, Charlotte Westergaard, Niels |
| author2_variant |
c v cv n w nw |
| author2_role |
HerausgeberIn Sonstige Sonstige |
| title |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| spellingShingle |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| title_sub |
Future Perspectives |
| title_full |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| title_fullStr |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| title_full_unstemmed |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| title_auth |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| title_alt |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_new |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy |
| title_sort |
clinical utility of applying pgx and deprescribing-based decision support in polypharmacy future perspectives |
| publisher |
MDPI Books |
| publishDate |
2022 |
| physical |
1 electronic resource (224 p.) |
| isbn |
3-0365-5162-X 3-0365-5161-1 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT vermehrencharlotte clinicalutilityofapplyingpgxanddeprescribingbaseddecisionsupportinpolypharmacyfutureperspectives AT westergaardniels clinicalutilityofapplyingpgxanddeprescribingbaseddecisionsupportinpolypharmacyfutureperspectives AT vermehrencharlotte clinicalutilityofapplyingpgxanddeprescribingbaseddecisionsupportinpolypharmacy AT westergaardniels clinicalutilityofapplyingpgxanddeprescribingbaseddecisionsupportinpolypharmacy |
| status_str |
n |
| ids_txt_mv |
(CKB)5680000000080797 (oapen)https://directory.doabooks.org/handle/20.500.12854/92141 (EXLCZ)995680000000080797 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Future Perspectives |
| author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
| _version_ |
1796652159386779648 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05205nam-a2201381z--4500</leader><controlfield tag="001">993560439504498</controlfield><controlfield tag="005">20231214133423.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202209s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000080797</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/92141</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000080797</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vermehren, Charlotte</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy</subfield><subfield code="b">Future Perspectives</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy </subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI Books</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (224 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical industries</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">acute kidney injury</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">early biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasma neutrophil gelatinase-associated lipocalin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">soluble urokinase plasminogen activator receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medication optimization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">older patients</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">emergency department</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multimorbidity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polypharmacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">potentially inappropriate medication use</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">older adults</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prevalence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">determinants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outpatient</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">2019 Beers criteria</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ethiopia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacogenomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">persons with diabetes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug–drug interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug–gene interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytochrome P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SLCO1B1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug interaction checkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse drug reactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacogenetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phenprocoumon</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DOACs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bleeding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">thromboembolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HLA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug hypersensitivity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">abacavir</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">allopurinol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">flucloxacillin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antiepileptic drugs</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cost-effectiveness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">shared medication record</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medication reconciliation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug information service</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hospital pharmacy service</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">electronic prescribing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">electronic medical record</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clinical pharmacist</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2D6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2D7P</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2D8P</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">copy number variation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CNV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genotyping</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">5’nuclease assay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HRM</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high resolution melting</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug metabolization</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extracellular vesicles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exosomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microvesicles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacogene expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medication review</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">deprescriptions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quality of life</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aged</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aged, 80 and over</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nursing homes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">deprescribing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medication-based risk score</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">health outcomes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytochromes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1A2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse drug reaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antipsychotics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">olanzapine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">clozapine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">loxapine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">children</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">youth</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">digital decision-support</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">health services research</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">general practice</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">process evaluation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antidepressants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">utility</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">population-based</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">appropriateness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">medication adherence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">digital health</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5162-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-5161-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Westergaard, Niels</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vermehren, Charlotte</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Westergaard, Niels</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:53:34 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5344130930004498&Force_direct=true</subfield><subfield code="Z">5344130930004498</subfield><subfield code="b">Available</subfield><subfield code="8">5344130930004498</subfield></datafield></record></collection> |